

AMCP eModel is the ultimate tool for communication of health economic models and value evidence. Find out more about this tech partnership and this health economic modeling platform to support the exchange of clinical and economic information between manufacturers and payers.

AMCP partners with FormularyDecisions to enhance information sharing and formulary decision-making by creating a platform for current, credible, and compliant information exchange between life science companies and active, qualified healthcare decision-makers.
Featured










-
Health Information Technology Resources
-
Digital Therapeutics Resources
-
Health Disparities Resources
-
Value-Based Contracts Resources
Meetings Proceedings & Findings
View More


Latest News & Resources

Hemophilia, sickle cell disease (SCD), and beta thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies.

Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. The etiology of ALS is unknown, however it is thought to be due to a combination of genetic predisposition, environmental exposures, and agingrelated dysfunction. The clinical presentation of ALS varies depending on which motor neurons are affected. ALS commonly presents with localized weakness that progresses to muscle paralysis, respiratory failure, and death.

AMCP brought together experts to learn about food allergies caused by the body reacting strongly to certain foods. Food allergies can be difficult to handle and costly for both people and the health care system. New medicines could help prevent allergic reactions, including anaphylaxis, caused by accidental exposure to foods. It is important for health care leaders to make sure people with food allergies see the right doctors, get the right medicine at the right time, and help prevent allergic reactions and related health care costs.

JMCP Outserts - Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. The National Institutes of Health estimated that cancer care cost the US $208.9 billion in 2020, $23.8 billion of which was due to lung cancer.
This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer.
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. On April 27, AMCP convened an expert panel of clinical and managed care stakeholders to increase understanding on how payers can inform strategies to improve the care and treatment of those impacted by ALS.

Hear from a panel of experts discussing bridging the gaps in precision oncology: opportunities in non-small cell lung cancer

Host Fred Goldstein invites Ruby Singh, Senior Vice President of Education and Instruction and Brittany Henry, Director of Education Programs, with AMCP, to discuss the brand-new 3rd edition of the AMCP Fundamentals of Managed Care Pharmacy Training Program scheduled for release July 2023.

Hear from a panel of experts discussing implementing continuous glucose monitoring interventions to improve outcomes for members with diabetes.

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.

Chronic lymphocytic leukemia (CLL) is a chronic
lymphoproliferative disorder (lymphoid neoplasm).
It is characterized by a progressive accumulation of
functionally incompetent B lymphocytes, which are
usually monoclonal in origin.

Hear from a panel of experts discussing exploring opportunities to improve quality of life for those with Amyotrophic Lateral Sclerosis (ALS).